ReviewAnnals of intensive care2020
Therapeutic strategies for critically ill patients with COVID-19.
Review in Annals of intensive care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinical effects of N-acetylcysteine in ICU patients with respiratory disease: a systematic review and meta-analysis.Respiratory research & clinical practice · 2026Pooled it
- A systematic review assessing the under-representation of elderly adults in COVID-19 trials.BMC geriatrics · 2020Pooled it
- A digital intervention for cognitive deficits following COVID-19: a randomized clinical trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Trial
- Olfactory Disturbances as Presenting Manifestation Among Egyptian Patients with COVID-19: Possible Role of Zinc.Biological trace element research · 2021Trial
- Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19.International journal of nanomedicine · 2021Trial
- Vitamin D Supplementation Improves Serological Parameters and Recovery Outcomes in COVID-19 Patients.Endocrine, metabolic & immune disorders drug targets · 2026Observational
- Clinical Pharmacist-Led Medication Review in Hospitalized Confirmed or Probable Patients with COVID-19 During the First Wave of COVID-19 Pandemic.Turkish journal of pharmaceutical sciences · 2024Article
- Alveolar Hyperoxia and Exacerbation of Lung Injury in Critically Ill SARS-CoV-2 Pneumonia.Medical sciences (Basel, Switzerland) · 2023Review
- [SARS-COV-2 pandemic: Involvement of the hospital pharmacist in securing patient care].Annales pharmaceutiques francaises · 2023Article
- Impact of nutritional therapy during the first wave of the COVID-19 pandemic in intensive care patients: A retrospective observational study.Clinical nutrition (Edinburgh, Scotland) · 2022Observational
- Changes Adopted in Asian Pediatric Hospitals during the COVID-19 Pandemic: A Report from the Pediatric Acute and Critical Care COVID-19 Registry of Asia.Journal of pediatric intensive care · 2022Article
- The impact of clinical pharmacist implemented education on the incidence of prescribing errors in COVID-19 patients.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Article
- Extracorporeal membrane oxygenation support in children with severe coronavirus disease-2019: A case series.Lancet regional health. Americas · 2022Article
- Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2022Review
- Acute Kidney Injury in Intensive Care Unit Patients with Coronavirus Disease 2019.Turkish journal of anaesthesiology and reanimation · 2022Article
- Article
- An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).International immunopharmacology · 2022Review
- Post-SARS-CoV-2 Acute Telogen Effluvium: An Expected Complication.Journal of clinical medicine · 2022Article
- A descriptive study of the surge response and outcomes of ICU patients with COVID-19 during first wave in Nordic countries.Acta anaesthesiologica Scandinavica · 2022Article
- Real-world use of inhaled nitric oxide therapy in patients with COVID-19 and mild-to-moderate acute respiratory distress syndrome.Drugs in context · 2022Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the 2019 novel coronavirus disease (COVID-19) outbreak originated from Wuhan, Hubei Province, China, at the end of 2019, it has become a clinical threat to the general population worldwide. Among people infected with the novel coronavirus (2019-nCoV), the intensive management of the critically ill patients in intensive care unit (ICU) needs substantial medical resource. In the present article, we have summarized the promising drugs, adjunctive agents, respiratory supportive strategies, as well as circulation management, multiple organ function monitoring and appropriate nutritional strategies for the treatment of COVID-19 in the ICU based on the previous experience of treating other viral infections and influenza. These treatments are referable before the vaccine and specific drugs are available for COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.